UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **October 3, 2022**

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction of incorporation)

001-35023	**26-2797813**
(Commission File Number)	*(IRS Employer Identification No.)*

8800 HSC Parkway
Bryan, Texas 77807
(Address of principal executive offices and zip code)

(979) 446-0027
(Registrant's telephone number including area code)

N/A
(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	IBIO	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

iBio, Inc. (the "Company") has updated its corporate presentation. A copy of the updated corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and in the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 99.1 is furnished with this Current Report on Form 8-K.

Exhibit Number	Exhibit Description
99.1	Corporate Presentation of iBio, Inc. dated October 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 3, 2022

IBIO, INC.

By: /s/ Thomas F. Isett
Name: Thomas F. Isett
Title: Chief Executive Officer

Exhibit 99.1

iBio

Growing Tomorrow's Biologics

CORPORATE PRESENTATION
October 2022

Tom Isett, Chairman & CEO

Forward-Looking Statements

Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this presentation. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to obtain regulatory approvals for commercialization of its product candidates, including IBIO-101, or to comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, its ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, its ability to retain its key employees or maintain its NYSE American listing, and the other factors discussed in the Company's most recent Annual Report on Form 10-K and the Company's subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this presentation is provided only as of today, and we undertake no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

iBio: A Biopharmaceutical Discovery & Development Company



Patented AI-Driven Discovery Engine

Identification and engineering of hard-to-target epitopes

***FastPharming*® Manufacturing Platform**

Proprietary plant-based protein expression system

***Glycaneering*SM Technology**

Advanced recombinant protein engineering

Development & Manufacturing Services

Delivering speed, scalability, and sustainability

Proprietary Pipeline

Focused on Immuno-Oncology


iBio
Platforms

Unique Solutions for Some of the Industry's Biggest Problems

Biopharmaceutical Development Challenges



Program Failures

Only ~5 in 5,000 drug concepts reach the clinic

Time / Cost

>1 year & ~$3-7M for scalable bioprocess & Ph1 material[1]

Biomanufacturing

Drug industry is 55% more emissions intensive than the auto industry[2]

Our Solutions

iBio SOLUTIONS

- Discovery Engine
- FastPharming®
- Glycaneering™

Dev/Mfg Services

[1]iBio estimates; [2]Belkhir, L., et. al. (2018) "Carbon footprint of the global pharmaceutical industry and relative impact of its major players". J Cleaner Production 214:185-194

RubrYc AI-Powered Discovery Engine: Drug Discovery for "Hard-to-Target" Binding Sites

The Problems



Subdominant Epitopes

Sites often missed with standard screening



Conformational Epitopes

Binding sites spread across amino acid chains

Our Solutions



Better Antibody Designs → Fewer Failures

iBio

*Patent Pending

End-to-End Computational Biology System for Enhanced Identification & Engineering of Large-Molecule Drug Candidates



FastPharming: Green Protein Expression System

FastPharming®
130,000 sf Facility

1



Seeding & Growth

Gene Cloning

Mobilization

2

Bacterial Infiltration
(Transient Transfection)

3

Protein
Production

4

Harvesting

5

Purification
& Vialing

The Speed & Scalability of *FastPharming* Potentially Enables a Faster, More Efficient Path to the Clinic



FastPharming® brings the capability to avoid the significant cost and time associated with selecting, developing & banking mammalian cell lines

Time to Drug Substance may vary and does not include product-specific process and assay development work.
Mammalian cell culture timelines shown are for illustrative purposes only based upon competitive data from publicly available sources. Actual timelines may vary.

iBio Platforms Potentially Enable More Promising Candidates to Reach the Clinic, Faster

Current Drug Development Challenge



Industry Benchmarks to Reach IND[1]		
Success Rate	Time	Cost
<5 in 5,000	>3 Years	>$20M

RubrYc Discovery Engine + FastPharming® + *Glycaneering*™ Technology





Increased Potency with **Glycaneering**

[1]https://www.researchgate.net/publication/265288848_The_Global_Biomedical_Industry_Preserving_US_Leadership

Reducing Single-Use Plastic Disposables in Upstream Processing



[1] 17th Annual Report and Summary of Biopharmaceutical Manufacturing Capacity and Production https://www.biopharma.com/TRENDS.pdf

Pipeline Growth Driven by Immuno-Oncology Program



*Developed using the RubriYc Discovery Engine


iBio
Immuno-Oncology

Deploying AI-based Target ID/Engineering & *Glycaneering* to Create More, Higher-Quality, Anti-Cancer Candidates

1. More shots-on-goal, sooner
2. Identifying failures earlier, saving costs
3. Accelerating development timelines

*As programs advance, additional opportunities to partner molecules and supply with **FastPharming** Services*



THERAPEUTICS

iBio

IBIO-101 (Lead Program) Stimulates Anti-tumor Immunity via anti-CD25 T_{reg} Depletion



THERAPEUTICS

2nd gen IL-2 sparing anti-CD25 antibody electively targets T_{regs} without blocking IL-2 signaling to T_{effs}

Positive IBIO-101/RTX-003 preclinical data are consistent with results from one other non-IL2 blocking anti-CD25 antibody that is now in a Phase I clinical trial[1]

iBio

[1]Data on file

T_{reg} = Regulatory T Cells; T_{eff} = Effector T Cells; ADCC = Antibody Dependent Cellular Cytotoxicity

Characteristics of Plant and CHO Made Molecules are Comparable



Antibody	k_{on} (M^{-1} s^{-1})	k_{off} (s^{-1})	K_D (nM)	K_D SD (nM)
RTX-003 WT	4.71E+05	1.92E-03	4.10	0.37
RTX-003 afuc	4.99E+05	1.91E-03	3.9	1.03
IBIO-101 WT	4.85E+05	1.96E-03	4.20	0.69
IBIO-101 afuc	4.92E+05	2.07E-03	4.27	1.27

IBIO-101 demonstrates equivalent binding kinetics compared with RTX-003

THERAPEUTICS

Phan, et al. "Plant-Based Expression and Glyco-Engineering of Novel IL-2 Signaling Permissive Anti-CD25 Antibodies for Effective Treg Depletion in Cancer"

FastPharming and CHO Produced Molecules Bind Potently to CD25, Which is Commonly Expressed by T_{reg} Cells



IBIO-101 and RTX-003 show nearly identical binding to recombinant human and non-human primate CD25, but don't cross react with recombinant mouse CD25 protein

THERAPEUTICS

Phan, et al. "Plant-Based Expression and Glyco-Engineering of Novel IL-2 Signaling Permissive Anti-CD25 Antibodies for Effective Treg Depletion in Cancer"

FastPharming and CHO Produced Molecules Bind to CD25-Positive Human Tumor Cells; and Don't Interfere with Important IL-2 Signaling





THERAPEUTICS

IBIO-101 and RTX-003 bind to SUDHL1 human lymphoma cells and don't interfere with IL-2 stimulated STAT5 activation

Phan, et al. "Plant-Based Expression and Glyco-Engineering of Novel IL-2 Signaling Permissive Anti-CD25 Antibodies for Effective Treg Depletion in Cancer"

FastPharming and CHO Produced Molecules Have Similar Potency and Efficacy in Cancer Cell Killing Assays





THERAPEUTICS

Efficacy and potency of IBIO-101 and RTX-003 are comparable in antibody-dependent cellular cytotoxicity assays using a reporter assay or primary human PBMC

iBio

Phan, et al. "Plant-Based Expression and Glyco-Engineering of Novel IL-2 Signaling Permissive Anti-CD25 Antibodies for Effective Treg Depletion in Cancer"

iBio

In Summary

Our Leadership Team Brings Drug Development & Bioprocessing Experience

Tom Isett
CEO & Chairman

- GE
- Lonza
- BD
- commence bio
- i.e. Advising

Martin Brenner, DVM, Ph.D.
CSO

- PFENEX
- AstraZeneca
- Lilly
- MERCK
- Pfizer

Robert Lutz, MBA
CFBO

- STRONGBRIDGE BIOPHARMA
- Shire
- Goldman Sachs

Marc Banjak
GC

- istari ONCOLOGY
- Dova PHARMACEUTICALS
- ICON
- B BRAUN SHARING EXPERTISE
- PPD

Lisa Middlebrook
CHRO

- LUPIN
- Lonza

Strong and Growing IP Estate Provides Exclusivity for iBio's Pipeline

107
Issued Patents
(25 U.S.)

32
Active Applications
(9 U.S.)

→ **More Applications** progressing to filing

Patent Protection Includes:

- Intellectual property [IP] around iBio's biopharmaceutical candidates
- IP related to the Drug Discovery platform (including Notice of Allowance from USPTO)
- IP related to the ***FastPharming*** Protein Expression System
- Elements of ***Glycaneering*** Service for advanced glycosylation controls in plants, including afucosylation for Antibody-Dependent Cellular Cytotoxicity [ADCC]

Continuing to Aggressively Defend our IP

- Settled *iBio v. Fraunhofer USA* for $28M in May 2021

iBio: Leveraging Capabilities

Combing platforms to create a biotech company with its own end-to-end discovery capabilities

Pipeline of promising immunotherapy candidates, with a focus on immuno-oncology

Leveraging patented platforms for both in-licensing and out-licensing